^
    1d
    DARATALL-VHR: Daratumumab in VHR T-ALL Treated According to the ALL National Treatment Program (clinicaltrials.gov)
    P2, N=31, Active, not recruiting, Gruppo Italiano Malattie EMatologiche dell'Adulto | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    CD38 (CD38 Molecule)
    |
    cyclophosphamide • Darzalex Faspro (daratumumab and hyaluronidase-fihj)
    1d
    GMMG-DADA: Daratumumab for First Line Treatment of Transplant-ineligible Myeloma Patients Followed by Daratumumab Re-treatment at First Relapse (clinicaltrials.gov)
    P2, N=67, Active, not recruiting, University of Cologne | Recruiting --> Active, not recruiting | N=160 --> 67 | Trial completion date: Dec 2029 --> Dec 2031 | Trial primary completion date: Dec 2029 --> Mar 2025
    Enrollment closed • Enrollment change • Trial completion date • Trial primary completion date
    |
    bortezomib • cyclophosphamide • Darzalex Faspro (daratumumab and hyaluronidase-fihj)
    8d
    Daratumumab, Pomalidomide, and Dexamethasone (DPd) in Relapsed/Refractory Light Chain Amyloidosis Patients Previously Exposed to Daratumumab (clinicaltrials.gov)
    P2, N=15, Active, not recruiting, Weill Medical College of Cornell University | Trial primary completion date: Jan 2026 --> Jan 2027
    Trial primary completion date
    |
    dexamethasone • pomalidomide • Darzalex Faspro (daratumumab and hyaluronidase-fihj)
    11d
    LINKER-MM8: A Study of Linvo-VR vs DVRd in Transplant-Eligible Adult Participants With Newly Diagnosed Multiple Myeloma (NDMM) (clinicaltrials.gov)
    P2/3, N=1570, Not yet recruiting, Regeneron Pharmaceuticals
    New P2/3 trial
    |
    lenalidomide • bortezomib • Darzalex Faspro (daratumumab and hyaluronidase-fihj) • Lynozyfic (linvoseltamab-gcpt)
    17d
    CT-P44 3.1: A study to compare Efficacy, Safety and How the Body Absorbs, Distributes, and Eliminates of Subcutaneous CT-P44 and Darzalex Faspro in Combination with Lenalidomide and Dexamethasone in Patients with Refractory or Relapsed Multiple Myeloma (2024-518588-36-00)
    P2/3, N=42, Recruiting, Celltrion Inc.
    New P2/3 trial
    |
    lenalidomide • dexamethasone • Darzalex Faspro (daratumumab and hyaluronidase-fihj)
    17d
    M25-059: A Study to Assess Change in Disease Activity and Adverse Events (AE)s in Adult Participants with Multiple Myeloma Receiving Etentamig (ABBV-383) as an Intravenous (IV) Infusion Alone or in combination with Oral, IV, Subcutaneous Daratumumab; Lenalidomide; Dexamethasone; Carfilzomib (2024-515770-27-00)
    P1/2, N=10, Not yet recruiting, AbbVie Deutschland GmbH & Co. KG
    New P1/2 trial • Adverse events
    |
    lenalidomide • carfilzomib • dexamethasone • Darzalex Faspro (daratumumab and hyaluronidase-fihj)
    21d
    Testing the Investigational Medication Combination of Daratumumab and Teclistamab Compared to the Usual Treatment (Daratumumab, Pomalidomide, Dexamethasone or Daratumumab, Carfilzomib, Dexamethasone) for Patients With High-risk Multiple Myeloma Refractory or in First Relapse (clinicaltrials.gov)
    P2, N=80, Not yet recruiting, National Cancer Institute (NCI) | Trial completion date: Feb 2026 --> Feb 2028 | Initiation date: Jan 2026 --> Apr 2026 | Trial primary completion date: Feb 2026 --> Feb 2028
    Trial completion date • Trial initiation date • Trial primary completion date
    |
    Chr del(17p)
    |
    clonoSEQ
    |
    carfilzomib • pomalidomide • Darzalex Faspro (daratumumab and hyaluronidase-fihj) • Tecvayli (teclistamab-cqyv) • Hemady (dexamethasone tablets) • dexamethasone injection
    28d
    LINKER-SMM2: A Study to Compare Linvoseltamab and Daratumumab Treatment in High-Risk Smoldering Multiple Myeloma (HR-SMM) (clinicaltrials.gov)
    P3, N=270, Not yet recruiting, Regeneron Pharmaceuticals
    New P3 trial
    |
    Darzalex Faspro (daratumumab and hyaluronidase-fihj) • Lynozyfic (linvoseltamab-gcpt)
    1m
    Combination Treatment Therapy Approaches for the Treatment of High-Risk Multiple Myeloma, REACH Trial (clinicaltrials.gov)
    P2, N=17, Active, not recruiting, Mayo Clinic | Recruiting --> Active, not recruiting | N=75 --> 17
    Enrollment closed • Enrollment change
    |
    TP53 (Tumor protein P53)
    |
    TP53 mutation
    |
    lenalidomide • carfilzomib • Darzalex Faspro (daratumumab and hyaluronidase-fihj) • Hemady (dexamethasone tablets) • dexamethasone injection
    2ms
    LINKER-MM5: A Study to Compare Linvoseltamab Monotherapy and Linvoseltamab + Carfilzomib Combination Therapy With Standard-of-Care Combination Regimens in Adult Participants With Relapsed/Refractory Multiple Myeloma (RRMM) (clinicaltrials.gov)
    P3, N=915, Recruiting, Regeneron Pharmaceuticals | Not yet recruiting --> Recruiting
    Enrollment open
    |
    bortezomib • carfilzomib • dexamethasone • pomalidomide • Darzalex Faspro (daratumumab and hyaluronidase-fihj) • Lynozyfic (linvoseltamab-gcpt)
    2ms
    MAGNETISMM-5: A Study to Learn About the Study Medicine Elranatamab Alone and With Daratumumab in People With Multiple Myeloma Who Have Received Other Treatments (clinicaltrials.gov)
    P3, N=944, Recruiting, Pfizer | Trial primary completion date: Dec 2025 --> Apr 2026
    Trial primary completion date
    |
    lenalidomide • dexamethasone • pomalidomide • Elrexfio (elranatamab-bcmm) • Darzalex Faspro (daratumumab and hyaluronidase-fihj)
    2ms
    Minimal Residual Disease Response-adapted Deferral of Transplant in Dysproteinemia (MILESTONE) (clinicaltrials.gov)
    P2, N=40, Recruiting, University of Alabama at Birmingham | N=20 --> 40 | Trial primary completion date: Jan 2026 --> Jan 2027
    Enrollment change • Trial primary completion date • Minimal residual disease
    |
    lenalidomide • bortezomib • cyclophosphamide • Darzalex Faspro (daratumumab and hyaluronidase-fihj)